Clinical trial reportBloodPublished
Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results
15 of 31 authors shown in byline order.
Regional connection
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
- Institution
- Johnson & Johnson
- County
- Montgomery County
Publication record
- Type
- Clinical trial report
- Venue
- Blood
- Published
- Topic
- Clinical care
- Subject terms
- Humans; Multiple Myeloma; Neoplasm, Residual; Thalidomide; Dexamethasone; Antineoplastic Combined Chemotherapy Protocols; Antibodies, Monoclonal; Adult; Aged; Middle Aged; Female; Male
- PubMed ID
- 40127397
- PubMed Central ID
- PMC13292241
- Open access
- Yes, accepted manuscript
- Added to directory
- Source checked